The Good Samaritan or Non-Directed Donor

2021 ◽  
pp. 147-172
Author(s):  
Lainie Friedman ◽  
J. Richard Thistlethwaite, Jr

From the outset of kidney transplantation, some living donors were “Good Samaritan” donors—that is, individuals who donated a kidney without a specific recipient in mind. However, non-genetically related donors fell out of favor quickly because the results were no better than deceased donor grafts. As immunosuppression improved and graft outcomes from non-biologically related donors improved, attitudes changed (with greater and earlier support from the public than from transplant professionals and with greater support for spouses then friends then acquaintances, and then strangers). This chapter examines ethical controversies raised by Good Samaritan donors using a living donor ethics framework. It examines the moral justification for permitting living donation by strangers, the ethics of the donor and recipient selection and allocation processes, and whether Good Samaritan donors should be encouraged to catalyze a domino multi-donor-recipient pair chain rather than donate to a single candidate on the waitlist.

2021 ◽  
Author(s):  
Tamar A.J. van den Berg ◽  
Marius C. van den Heuvel ◽  
Janneke Wiersema-Buist ◽  
Jelle Adelmeijer ◽  
Gertrude J. Nieuwenhuijs-Moeke ◽  
...  

Abstract In kidney transplantation, microthrombi and fibrin deposition may lead to local perfusion disorders and subsequently poor initial graft function. Microthrombi are often regarded as donor-derived. However, the incidence, time of development, and potential difference between living donor kidneys (LDK) and deceased donor kidneys(DDK), remains unclear. Two open-needle biopsies, taken at preimplantation and after reperfusion, were obtained from 17 LDK and 28 DDK transplanted between 2005 and 2008. Paraffin-embedded sections were immunohistochemically stained with anti-fibrinogen antibody. Fibrin deposition intensity in peritubular capillaries(PTC) and glomeruli was categorized as negative, weak, moderate or strong and the number of microthrombi/mm2 was quantified. Reperfusion biopsies showed more fibrin deposition (20–100% moderate/strong, p < 0.001) and more microthrombi/mm2 (0.97 ± 1.12 vs. 0.28 ± 0.53, p < 0.01) than preimplantation biopsies. In addition, more microthrombi/mm2 (0.38 ± 0.61 vs. 0.09 ± 0.22, p = 0.02) and stronger fibrin intensity in glomeruli (28% vs. 0%, p < 0.01) and PTC (14% vs. 0%, p = 0.02) were observed in preimplantation DDK than LDK biopsies. After reperfusion, microthrombi/mm2 were comparable (p = 0.23) for LDK (0.09 ± 0.22 to 0.76 ± 0.49, p = 0.03) and DDK (0.38 ± 0.61 to 0.90 ± 1.11, p = 0.07). Upon reperfusion, there is an aggravation of microthrombus formation and fibrin deposition within the graft. The prominent increase of microthrombi in LDK indicates that they are not merely donor-derived.


2020 ◽  
Vol 2020 ◽  
pp. 1-4
Author(s):  
Gaia Peluso ◽  
Silvia Campanile ◽  
Alessandro Scotti ◽  
Vincenzo Tammaro ◽  
Akbar Jamshidi ◽  
...  

Introduction. SARS-CoV-2 is a virus that causes a potentially deadly syndrome that affects especially the respiratory tract. Kidney-transplanted patients are immunosuppressed and more susceptible to viral infections. We have examined our transplantation activity to explore the future role of kidney transplantation from deceased and living donors in COVID-19 era. Patients and Methods. The activity of our transplant center of Naples (one of the two transplant centers in Campania, South Italy) continued during the COVID-19 pandemic. We have analysed the kidney transplants carried out between March 9 and June 9, 2020, comparing these data with the numbers of procedures performed in the two previous years. Moreover, we have considered the possibility of performing living donor transplants during a worldwide pandemic. Results. From March 9, 2020, when the Italian lockdown begun, till June 9, 2020, five kidney transplants have been performed at our transplant center in Naples, all from deceased donors. The donors and the recipients have been screened for COVID-19 infection, and the patients, all asymptomatic, followed strict preventive measures and were fully informed about the risks of surgery and immunosuppression during a pandemic. All the transplanted patients remained COVID negative during the follow-up. The number of transplants performed has been constant compared to the same months of 2018 and 2019. In agreement with the patients, we decided to postpone living donor transplants to a period of greater control of the SARS-CoV-2 spread in Italy. Conclusion. Deceased donor kidney transplantation should continue, especially in a region with moderate risk, like Campania, with a more careful selection of donors and recipients, preferring standard donors and recipients without severe comorbidities. Living donor transplantation program, instead, should be postponed to a period of greater control of the SARS-CoV-2 spread, as it is an elective surgery and its delay does not determine additional risks for patients.


2006 ◽  
Vol 20 (5) ◽  
pp. 339-343 ◽  
Author(s):  
Shimul A Shah ◽  
Gary A Levy ◽  
Lesley D Adcock ◽  
Gary Gallagher ◽  
David R Grant

The present review outlines the principles of living donor liver transplantation, donor workup, procedure and outcomes. Living donation offers a solution to the growing gap between the need for liver transplants and the limited availability of deceased donor organs. With a multidisciplinary team focused on donor safety and experienced surgeons capable of performing complex resection/reconstruction procedures, donor morbidity is low and recipient outcomes are comparable with results of deceased donor transplantation.


2021 ◽  
pp. ASN.2020081242
Author(s):  
Adrian M. Whelan ◽  
Kirsten L. Johansen ◽  
Sandeep Brar ◽  
Charles E. McCulloch ◽  
Deborah B. Adey ◽  
...  

BackgroundTransplant candidates may gain an advantage by traveling to receive care at a transplant center that may have more favorable characteristics than their local center. Factors associated with longer travel distance for transplant care and whether the excess travel distance (ETD) is associated with access to transplantation or with graft failure are unknown.MethodsThis study of adults in the United States wait-listed for kidney transplantation in 1995–2015 used ETD, defined as distance a patient traveled beyond the nearest transplant center for initial waiting list registration. We used linear regression to examine patient and center characteristics associated with ETD and Fine–Gray models to examine the association between ETD (modeled as a spline) and time to deceased or living donor transplantation or graft failure.ResultsOf 373,365 patients, 11% had an ETD≥50 miles. Traveling excess distance was more likely among patients who were of non-Black race or those whose nearest transplant center had lower annual living donor transplant volume. At an ETD of 50 miles, we observed a lower likelihood of deceased donor transplantation (subhazard ratio [SHR], 0.85; 95% confidence interval [95% CI], 0.84 to 0.87) but higher likelihood of living donor transplantation (SHR, 1.14; 95% CI, 1.12 to 1.16) compared with those who received care at their nearest center. ETD was weakly associated with higher risk of graft failure.ConclusionsPatients who travel excess distances for transplant care have better access to living donor but not deceased donor transplantation and slightly higher risk of graft failure. Traveling excess distances is not clearly associated with better outcomes, especially if living donors are unavailable.


2020 ◽  
Author(s):  
Anneke Kramer ◽  
Rianne Boenink ◽  
Vianda S Stel ◽  
Carmen Santiuste de Pablos ◽  
Filip Tomović ◽  
...  

Abstract Background The ERA-EDTA Registry collects data on kidney replacement therapy (KRT) via national and regional renal registries in Europe and countries bordering the Mediterranean Sea. This article summarizes the 2018 ERA-EDTA Registry Annual Report, and describes the epidemiology of KRT for kidney failure in 34 countries. Methods Individual patient data on patients undergoing KRT in 2018 was provided by 34 national or regional renal registries and aggregated data by 17 registries. The incidence and prevalence of KRT, the kidney transplantation activity and the survival probabilities of these patients were calculated. Results In 2018, the ERA-EDTA Registry covered a general population of 636 million people. Overall, the incidence of KRT for kidney failure was 129 per million population (pmp), 62% of patients were men, 51% were ≥65 years of age and 20% had diabetes mellitus as cause of kidney failure. Treatment modality at the onset of KRT was haemodialysis for 84%, peritoneal dialysis for 11% and pre-emptive kidney transplantation for 5% of patients. On 31 December 2018, the prevalence of KRT was 897 pmp, with 57% of patients on haemodialysis, 5% on peritoneal dialysis, and 38% living with a kidney transplant. The transplant rate in 2018 was 35 pmp: 68% received a kidney from a deceased donor, 30% from a living donor, and for 2% the donor source was unknown. For patients commencing dialysis during 2009-2013, the unadjusted 5-year survival probability was 42.6%. For patients receiving a kidney transplant within this period the unadjusted 5-year survival probability was 86.6% for recipients of deceased donor grafts, and 93.9% for recipients of living donor grafts.


2021 ◽  
Author(s):  
◽  
Paula Marie Martin

<p>Increasing numbers of New Zealanders are experiencing end-stage renal failure, requiring kidney transplantation or dialysis. A transplant from a living kidney donor is the preferred treatment, offering better quality of life than dialysis, and greater life expectancy and cost-effectiveness than dialysis and deceased donor transplantation. Living donor transplant rates in New Zealand have plateaued and may even be declining at a time when many comparable countries are experiencing sustained increases. Viewing this issue as a complex policy problem, this research aimed to identify how rates of living donor kidney transplantation could be increased in New Zealand. Based on Walt and Gilson’s health policy triangle, which suggests that understanding policy issues requires attention not only to content (policy options) but also processes, contextual issues and actors, this research asked firstly, what the barriers are for patients in the journey to living donor transplantation, and secondly, why greater attention has not been paid to how to increase current rates, given evidence of better outcomes for patients and cost-effectiveness.  The research took a patient-centred, systems perspective and used a pragmatic, interdisciplinary, mixed-methods research design. Methods included a survey of kidney transplant waiting-list patients; interviews with patients, renal health professionals and key informants; document analysis; and a survey of health managers. A Five-Stage Model of the living donor kidney transplant process was developed to map specific barriers in the journey to transplantation and Kingdon’s multiple streams agenda-setting model was used to examine the issue of why so little attention had been paid to living donor kidney transplantation in New Zealand.  The research found that, in common with patients elsewhere, New Zealand patients are not systematically informed about living donor transplantation, would like to receive a transplant but have concerns about health and financial impacts on donors, and face challenges in approaching people in their networks about living donation. Incompatibility and medical unsuitability are major barriers for potential donors who do come forward. Issues with existing service models, configuration of key roles in transplant services, and delays in donor work-up processes are all evident. Perceived ethical constraints may limit how willing health professionals are to promote living donation, requiring both potential recipients and donors to be very proactive to successfully navigate the living donation process.  There has been political will to address organ shortages in the past but there has been little focus specifically on live donation. An absence of feasible and acceptable options for decision-makers to consider, crowding-out by demand for dialysis services, lack of leadership, absence of an effective advocate, and issues in funding and accountability arrangements may all have contributed to why live kidney transplantation has not had more prominence on the policy agenda in New Zealand in recent years.  Overall, the research concludes that policy and practice in the wider system are not adequately oriented to supporting living donor kidney transplantation as the preferred treatment for end-stage renal failure. A comprehensive national strategy for increasing New Zealand’s rate is recommended.</p>


2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Chava Ramspek ◽  
Mostafa El Moumni ◽  
Martin Heemskerk ◽  
Eelaha Wali ◽  
Nichon Jansen ◽  
...  

Abstract Background and Aims With rising demand for kidney transplantation and the kidney donor pool lagging behind, the acceptance criteria for donor kidneys are expanding. Hence, reliable pre-transplant assessment of organ quality has become a top priority. Estimating the risk of adverse outcomes at the time of kidney allocation is challenging and particularly relevant for recipients of kidneys from older donors. The existing kidney donor risk index (KDRI) has been criticized for heavily depending on donor age. Therefore, the aim of the current study was to develop and validate a prediction model for adverse outcome after kidney transplantation from deceased donors aged 50 years or older and compare this model’s performance to the KDRI. Method We utilized the Dutch kidney transplant registry (NOTR) and identified patients who received a kidney from a deceased donor aged 50 years or older between 2006 and 2019. These recipients were included for model development and temporal validation. The prediction model was externally validated on the United States organ transplantation registry (OPTN), in which we selected patients that were transplanted between 2006 and 2017. Potential pre-transplant predictors were selected by an expert panel of nephrologists and surgeons. The predicted adverse outcome was defined as a composite of graft failure, recipient mortality or CKD stage 4/5 within 1 year of transplantation. A logistic regression model was developed, internally validated and shrunk for optimism through bootstrapping. Missing data were multiply imputed in 10-fold, non-linear continuous predictors were modelled with restricted cubic splines and clinically relevant interaction terms were included. The KDRI was validated on the same NOTR and OPTN cohorts for graft survival within 1 year. The developed model and the KDRI were recalibrated to the baseline risk of outcome in external validation. Model performance was assessed by discrimination and calibration. Results The model was developed on 2510 patients of whom 823 experienced an adverse outcome within the first year. The temporal validation cohort contained 837 patients of whom 230 had an adverse outcome and the US external validation cohort consisted of 31987 patients with 6758 adverse outcomes. Selected donor predictors were: age, gender, BMI, cause of death, CPR, inotropes use, serum creatinine, hypertension, hypotension, diabetes, smoking, left/right kidney, warm ischemic time, cold ischemic time and proteinuria. Recipient predictors were: age, gender, BMI, diabetes, cardiovascular comorbidity, primary kidney disease, dialysis duration, number of previous kidney transplantations, HLA mismatches and PRA. Discrimination of the adverse outcome model was moderate, yet considerably better than discrimination of the KDRI (see table). The adverse outcome model’s calibration and distribution of predicted risks were good in both the NOTR and OPTN (see figure). Conclusion A prediction model was developed and extensively validated for adverse outcome after kidney transplantation from older deceased donors. Despite the use of advanced and robust methodology, its discriminatory capacity was limited. However, the adverse outcome model showed good calibration and performed considerably better than the KDRI in this population of suboptimal donors. This model could potentially assist nephrologists in deciding whether to accept or decline a specific kidney from an older deceased donor.


Sign in / Sign up

Export Citation Format

Share Document